E-LIB Suche - Ergebnisse für: Andersen, Scott W.

1

Assessment of Efficacy and Safety of Zagotenemab: Results F..:

Fleisher, Adam S. ; Munsie, Leanne M. ; Perahia, David G.S....
Neurology. 102 (2024) 5 - p. , 2024

Link: https://doi.org/10.1212/..

2

APOE ε4's impact on response to amyloid therapies in early ..:

Evans, Cynthia D. ; Sparks, JonDavid ; Andersen, Scott W....
Alzheimer's & Dementia. 19 (2023) 12 - p. 5407-5417 , 2023

Link: https://doi.org/10.1002/..

3

Safety, Tolerability, and Pharmacokinetics of Zagotenemab i..:

Willis, Brian A. ; Lo, Albert C. ; Dage, Jeffrey L....
Journal of Alzheimer's Disease Reports. 7 (2023) 1 - p. 1015-1024 , 2023

Link: https://doi.org/10.3233/..

4

Reproducibility of applying multiple statistical analyses t..:

Sparks, JonDavid ; Lo, Albert C. ; Evans, Cynthia Duggan...
Alzheimer's & Dementia. 17 (2021) S9 - p. , 2021

Link: https://doi.org/10.1002/..

5

TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after ..:

Shcherbinin, Sergey ; Andersen, Scott W. ; Evans, Cynthia Duggan...
Alzheimer's & Dementia. 17 (2021) S9 - p. , 2021

Link: https://doi.org/10.1002/..

6

Lanabecestat: Neuroimaging results in early symptomatic Alz..:

Zimmer, Jennifer A. ; Shcherbinin, Sergey ; Devous Sr., Michael D....
Alzheimer's & Dementia: Translational Research & Clinical Interventions. 7 (2021) 1 - p. , 2021

Link: https://doi.org/10.1002/..

7

Novel use of tau imaging to enrich for pathological homogen..:

Munsie, Leanne M ; Lo, Albert C. ; Fleisher, Adam S...
Alzheimer's & Dementia. 17 (2021) S9 - p. , 2021

Link: https://doi.org/10.1002/..

8

Cognitive outcomes in trials of two BACE inhibitors in Alzh..:

Wessels, Alette M. ; Lines, Christopher ; Stern, Robert A....
Alzheimer's & Dementia. 16 (2020) 11 - p. 1483-1492 , 2020

Link: https://doi.org/10.1002/..

9

Disease Modification in Alzheimer's Disease: Current Thinki..:

Liu-Seifert, Hong ; Schumi, Jennifer ; Miao, Xiaopeng...
Therapeutic Innovation & Regulatory Science. 54 (2020) 2 - p. 396-403 , 2020

Link: https://doi.org/10.1007/..

10

Reasons for study exclusion by sex in lanabecestat studies ..:

Zimmer, Jennifer A. ; Andersen, Scott W. ; Wessels, Alette M...
Alzheimer's & Dementia. 16 (2020) S9 - p. , 2020

Link: https://doi.org/10.1002/..

11

Clinically Negligible Pharmacokinetic and Pharmacodynamic I..:

Monk, Scott A. ; Kugler, Alan R. ; Andersen, Scott W....
The Journal of Clinical Pharmacology. 60 (2019) 5 - p. 586-594 , 2019

Link: https://doi.org/10.1002/..

12

Disease Modification in Alzheimer's Disease: Current Thinki..:

Liu-Seifert, Hong ; Schumi, Jennifer ; Miao, Xiaopeng...
Therapeutic Innovation & Regulatory Science. , 2019

Link: https://doi.org/10.1177/..

13

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI..:

Yaari, Roy ; Holdridge, Karen C. ; Andersen, Scott W....
Alzheimer's & Dementia. 15 (2019) 7S_Part_7 - p. , 2019

Link: https://doi.org/10.1016/..

14

FTS3‐01‐02: SUBGROUP POPULATIONS IN AMARANTH, A RANDOMIZED ..:

Tariot, Pierre N. ; Selzler, Katherine J. ; Wessels, Alette M....
Alzheimer's & Dementia. 15 (2019) 7S_Part_17 - p. , 2019

Link: https://doi.org/10.1016/..

15

Assessment of Transporter Polymorphisms as a Factor in a BC..:

Willis, Brian A. ; Andersen, Scott W. ; Ayan‐Oshodi, Mosun...
The Journal of Clinical Pharmacology. 60 (2019) 1 - p. 107-116 , 2019

Link: https://doi.org/10.1002/..